Postoperative Carcinoembryonic Antigen as a Complementary Tumor Marker of Carbohydrate Antigen 19-9 in Pancreatic Ductal Adenocarcinoma

다국어 초록 (Multilingual Abstract)

The role of carcinoembryonic antigen (CEA) in pancreatic cancer remains poorlyunderstood. Therefore, this study aimed to determine whether CEA is complementary tocarbohydrate antigen 19-9 (CA19-9) in prognosis prediction after pancreatic cancercurative resection. We retrospectively reviewed records of 144 stage II curatively resectedpancreatic cancer patients with preoperative and postoperative CEA and CA19-9 levels.
Patients with normal preoperative CA19-9 were excluded. R0 resection margin, adjuvanttreatment, and absence of angiolymphatic invasion were associated with better overallsurvival. There was no significant difference in median survival according to preoperativeCEA levels. However, patients with normal postoperative CA19-9 (59.8 vs.16.2 months,P < 0.001) and CEA (29.4 vs. 9.3 months, P = 0.001) levels had longer overall survivalthan those with elevated levels. Among 76 patients with high postoperative CA19-9 levels,a better prognosis was observed in those with normal postoperative CEA levels than inthose with elevated levels (19.1 vs. 9.3 months, P = 0.004). Postoperative CEA and CA19-9 levels are valuable prognostic markers in resected pancreatic cancer. Normalpostoperative CEA levels indicate longer survival, even in patients with elevatedpostoperative CA19-9.

참고문헌 (Reference)

1 Lundin J, "The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer" 69 : 515-519, 1994

2 Humphris JL, "The prognostic and predictive value of serum CA19.9 in pancreatic cancer" 23 : 1713-1722, 2012

3 Zamcheck N., "The present status of carcinoembryonic antigen (CEA) in diagnosis, detection of recurrence, prognosis and evaluation of therapy of colonic and pancreatic cancer" 5 : 625-638, 1976

4 Ni XG, "The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer" 31 : 164-169, 2005

5 Gold P, "Specific carcinoembryonic antigens of the human digestive system" 122 : 467-481, 1965

6 Koprowski H, "Specific antigen in serum of patients with colon carcinoma" 212 : 53-55, 1981

7 Podolsky DK, "Serologic markers in the diagnosis and management of pancreatic carcinoma" 8 : 822-830, 1984

8 Motoi F, "Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines" 18 : 371-379, 2011

9 Yasue M, "Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer" 9 : 735-740, 1994

10 Hata S, "Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer" 19 : 636-641, 2012

11 Montgomery RC, "Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas" 4 : 551-556, 1997

12 Ferrone CR, "Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma" 24 : 2897-2902, 2006

13 Sener SF, "Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database" 189 : 1-7, 1999

14 Herlyn M, "Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma" 2 : 135-140, 1982

15 Conlon KC, "Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors" 223 : 273-279, 1996

16 Butturini G, "Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials" 143 : 75-83, 2008

17 Kim BJ, "How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?" 41 : 364-369, 2009

18 Distler M, "Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma" 13 : 12-, 2013

19 Satake K, "Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases" 80 : 630-636, 1985

20 Schlitter AM, "Definition of microscopic tumor clearance(r0)in pancreatic cancer resections" 2 : 2001-2010, 2010

21 Koprowski H, "Colorectal carcinoma antigens detected by hybridoma antibodies" 5 : 957-971, 1979

22 Tsavaris N, "CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis" 21 : 673-680, 2009